

REMARKS

For the convenience of the Examiner, it is noted that this application is a divisional of US 08/456,670, in which claims 1-2 and 11-14, drawn to isolated DNA molecules and methods of using them, have been allowed. Those claims have been cancelled in the instant application. US 08/456,670, in turn, claims priority to US 08/075,248 and 08/412,227, both of which were prosecuted with regard to claims drawn to antibodies and/or methods of making them, and both of which applications are now abandoned.

Please transfer to the instant case the CRF diskette (computer readable copy) and the paper copy of the sequence listing which were filed on November 30, 1998 in the parent case, 08/456,670.

With regard to the amendments to the specification:

The amendment to sequence IVf on page 5 corrects an inadvertent error, in accordance with the correct sequence in original claim 3 (one Val residue was omitted in the sequence in the specification).

The amendment to sequence IVg on page 5 corrects an obvious error of capitalizing the "X" in X⁴ in accordance with the rest of the nomenclature.

The amendment on page 20 of "again" to "against" is self-evident in the context of the sentence.

The amendments to the specification and claims concerning SEQ ID NO's are for the purpose of putting the application in compliance with 37 C.F.R. § 1.821-1.825 and conform to the sequence listing .


These amendments to the specification correct obvious inadvertent errors which are supported by other disclosures (e.g., in the claims) or are obvious to a skilled worker; the amendments are fully supported in the specification.

With regard to the amendments to the claims:


These amendments focus the prosecution in the present application on antibodies specific for pathogenic listerias, i.e., *Listeria monocytogenes*. This is not to be construed as acquiescence to any prior art rejections in the ancestor application, 08/075,248 (now abandoned), but rather is being done to expedite prosecution of claims relating to aspects of the present invention. Therefore, the full scope of equivalents applies.

Applicants expressly reserve the right to pursue any cancelled subject matter in a continuing application. The newly added claims recite specific embodiments of the invention and are fully supported in the specification.

Respectfully submitted,



Richard M. Lebovitz (Reg. No. 37,067)
Attorney for Applicants



Nancy J. Axelrod (Reg. No. 44,014)
Patent Agent

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
(703) 243-6333

RML/NJA/wks

Filed: **August 11, 1999**

K:\PAT\Merck\1694d2\PreAmd.wpd

03202200